Integra LifeSciences says Cincinnati plant flooding will cost millions

Integra LifeSciences (IART) expects millions in lost revenue due to flooding at its Cincinnati plant, lowering its 2026 financial forecasts. The company estimates a $7M revenue cut in Q3 and an additional $15M-$20M impact for the year. Full recovery is expected by Q2 2027. The stock dropped 16% to $13.50 on the news.

Original reporting
Published Oct 2, 2026, 3:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 4:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Integra LifeSciences says Cincinnati plant flooding will cost millions — source image
Decision brief

The 30-second read

$IARTBearishHigh
01

Why it matters

The incident forces a revenue shortfall, guidance reduction, and a share price decline, while insurance may cover part of the loss.

02

Market read

First‑report of a material operational disruption that materially lowers guidance and triggers a sharp stock move.

03

What to watch

Potential demand surge for Integra's products post‑recovery could support a rebound.

Relevance 7/10Novelty 7/10Timing: today

Background

Heavy rains caused flash flooding in Cincinnati, damaging Integra's plant that produces specialty surgical technologies.

Company-level read

Ticker impact

$IARTBearishHigh confidence
Context

Integra LifeSciences disclosed flood damage at its Cincinnati plant, cutting Q3 revenue by $7M and lowering full-year guidance, causing a 16% stock drop.

Expected impact

likely further downside as investors price in delayed production and reduced cash flow

Evidence & confidence

Guidance cut of $15‑$20M and a 16% price decline indicate material impact; insurance may offset some loss but recovery extends into 2027.

Market effects

Specialty surgical device sector may see short‑term pressure as supply disruptions raise concerns.

Midwest manufacturing outlook slightly weakened by flood risk.

Limited to Integra; no broad market effect.

Counterpoint

Insurance recovery could mitigate earnings hit, making the stock oversold.

Key entities

  • Integra LifeSciences

    Medical device maker reporting flood‑related losses.

  • Stuart Essig

    CEO of Integra LifeSciences providing the statement.

Related articles

$IARTMedAI 8/10

IART Q3 deep dive: Cincinnati disruption and Tissue Reconstruction challenges weigh on outlook

Integra LifeSciences (IART) reported Q3 operating margin of 4.6%, down from 9.9% YoY. Management cut full-year Adjusted EPS guidance to $2.35 midpoint, citing Cincinnati facility disruption and Tissue Reconstruction challenges. Neurosurgery growth offset some weaknesses. Debt refinancing improved liquidity, but higher interest expense is expected. Recovery from flood impact anticipated by mid-2027.